US Food and Drug Administration (FDA) ordersPfizer Inc PFE.N to test additional courses of antiviral drugs for efficacy Paxlovid was among those who experienced a rebound of COVID-19 after treatment, regulators said Friday.
In his letter dated August 5, the FDA required Pfizer to provide first results from a randomized controlled trial of a second course of antiviral drugs by September 30 next year. said there is.
READ MORE: Health Canada approves first COVID-19 booster for children ages 5-11
Regulators expect clinical trials to be completed later this month.
Pfizer is "working with the FDA to finalize protocols to study patients who may need retreatment," and will provide more details as they become available, a company spokesperson said.
Story Continues Below Advertisement
(Reporting by Leroy Leo, Bangalore, Editing by Aditya Soni)
© 2022 Reuters
